A randomized phase III clinical study of bevacizumab plus capecitabine vs. bevacizumab alone as maintenance therapy in patients with HER2-negative metastatic breast cancer that has not progressed during first-line docetaxel plus bevacizumab therapy.

Trial Profile

A randomized phase III clinical study of bevacizumab plus capecitabine vs. bevacizumab alone as maintenance therapy in patients with HER2-negative metastatic breast cancer that has not progressed during first-line docetaxel plus bevacizumab therapy.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 10 Dec 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine (Primary)
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms IMELDA
  • Sponsors Roche
  • Most Recent Events

    • 13 Dec 2014 Results of a post-hoc analysis comparing patient reported outcomes presented at the 37th Annual San Antonio Breast Cancer Symposium.
    • 28 Sep 2014 Results presented at the 39th European Society for Medical Oncology Congress.
    • 25 Sep 2014 Results published in the Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top